Public health service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use.
D002170:Canada; D015658:HIV Infections / Q000517:prevention & control; D006679:HIV Seropositivity; D006280:Health Workforce; D006801:Humans; D009784:Occupational Diseases / Q000517:prevention & control; D016273:Occupational Exposure; D011635:Public Health Administration; D012307:Risk Factors; D015215:Zidovudine / Q000627:therapeutic use*
D015215:Zidovudine